[go: up one dir, main page]

WO2001068708A3 - Human and humanized fap-alpha-specific antibodies - Google Patents

Human and humanized fap-alpha-specific antibodies Download PDF

Info

Publication number
WO2001068708A3
WO2001068708A3 PCT/EP2001/004716 EP0104716W WO0168708A3 WO 2001068708 A3 WO2001068708 A3 WO 2001068708A3 EP 0104716 W EP0104716 W EP 0104716W WO 0168708 A3 WO0168708 A3 WO 0168708A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
human
specific antibodies
fap
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/004716
Other languages
French (fr)
Other versions
WO2001068708A9 (en
WO2001068708A2 (en
Inventor
John-Edward Park
Pilar Garin-Chesa
Klaus Pfizenmaier
Dieter Moosmayer
Michael Mersmann
Alexej Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10013286A external-priority patent/DE10013286A1/en
Priority claimed from GB0022216A external-priority patent/GB0022216D0/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to AU2001256325A priority Critical patent/AU2001256325A1/en
Priority to JP2001567798A priority patent/JP2003530092A/en
Priority to EP01929604A priority patent/EP1268550A2/en
Priority to CA002401252A priority patent/CA2401252A1/en
Publication of WO2001068708A2 publication Critical patent/WO2001068708A2/en
Publication of WO2001068708A3 publication Critical patent/WO2001068708A3/en
Anticipated expiration legal-status Critical
Publication of WO2001068708A9 publication Critical patent/WO2001068708A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to antibody proteins which specifically bind fibroblast activating protein alpha (FAPα). The invention further relates to the use of said antibodies for diagnostic and therapeutic purposes as well as processes for preparing said antibodies.
PCT/EP2001/004716 2000-03-17 2001-03-16 Human and humanized fap-alpha-specific antibodies Ceased WO2001068708A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001256325A AU2001256325A1 (en) 2000-03-17 2001-03-16 Human and humanized fap-alpha-specific antibodies
JP2001567798A JP2003530092A (en) 2000-03-17 2001-03-16 Human FAP-α-specific antibody
EP01929604A EP1268550A2 (en) 2000-03-17 2001-03-16 Human fap-alpha-specific antibodies
CA002401252A CA2401252A1 (en) 2000-03-17 2001-03-16 Human and humanized fap-alpha-specific antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10013286.3 2000-03-17
DE10013286A DE10013286A1 (en) 2000-03-17 2000-03-17 New human humanized antibody that specifically binds to fibroblasts activating protein alpha, useful for treating cancer or tumor, and for imaging tumors associated with activated stromal fibroblasts, e.g. lung or breast cancer
GB0022216.6 2000-09-11
GB0022216A GB0022216D0 (en) 2000-09-11 2000-09-11 Human FAP-a-specific antibodies for use in cancer therapy

Publications (3)

Publication Number Publication Date
WO2001068708A2 WO2001068708A2 (en) 2001-09-20
WO2001068708A3 true WO2001068708A3 (en) 2002-05-02
WO2001068708A9 WO2001068708A9 (en) 2003-05-22

Family

ID=26004887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004716 Ceased WO2001068708A2 (en) 2000-03-17 2001-03-16 Human and humanized fap-alpha-specific antibodies

Country Status (5)

Country Link
EP (1) EP1268550A2 (en)
JP (1) JP2003530092A (en)
AU (1) AU2001256325A1 (en)
CA (1) CA2401252A1 (en)
WO (1) WO2001068708A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20021080A1 (en) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
PE20131209A1 (en) 2010-08-13 2013-10-25 Roche Glycart Ag ANTI-FAP ANTIBODIES
IL269687B (en) 2011-02-10 2022-08-01 Roche Glycart Ag Mutant interleukin-2 polypeptides
UA118028C2 (en) 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
WO2014167083A1 (en) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
EP3331564B1 (en) 2015-08-07 2025-01-08 Imaginab, Inc. Antigen binding constructs to target molecules
RU2758007C2 (en) 2016-06-30 2021-10-25 Онкорус, Инк. Delivery of therapeutic polypeptides via pseudotyped oncolytic viruses
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
MA47215A (en) 2017-01-09 2019-11-13 Bioxcel Therapeutics Inc PREDICTIVE AND DIAGNOSTIC PROCEDURES FOR PROSTATE CANCER
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CA3145872A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN118406106A (en) 2019-07-08 2024-07-30 3B制药有限公司 Compounds containing fibroblast activation protein ligands and uses thereof
KR102363980B1 (en) * 2020-04-13 2022-02-15 전남대학교산학협력단 Biomarker for diagnosis or prognosis analysis of brain metastasis and diagnosis method using same
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
MX2023007869A (en) 2021-01-07 2023-09-22 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof.
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN121342995A (en) * 2021-12-30 2026-01-16 乐普生物科技股份有限公司 Human antibody against FAP-Alpha
JP2025532754A (en) 2022-10-07 2025-10-03 ジェネトン Immunotherapy for skeletal myopathy using anti-FAP CAR-T cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029233A1 (en) * 1994-04-20 1995-11-02 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULE CODING FOR FIBROBLAST ACTIVATION PROTEIN α AND USES THEREOF
WO1999057151A2 (en) * 1998-04-30 1999-11-11 Boehringer Ingelheim International Gmbh FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029233A1 (en) * 1994-04-20 1995-11-02 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULE CODING FOR FIBROBLAST ACTIVATION PROTEIN α AND USES THEREOF
WO1999057151A2 (en) * 1998-04-30 1999-11-11 Boehringer Ingelheim International Gmbh FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BREITLING F ET AL: "A SURFACE EXPRESSION VECTOR FOR ANTIBODY SCREENING", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 104, 1991, pages 147 - 153, XP002046118, ISSN: 0378-1119 *
RADER CHRISTOPH ET AL: "A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 15, 21 July 1998 (1998-07-21), July 21, 1998, pages 8910 - 8915, XP002182776, ISSN: 0027-8424 *
RETTIG ET AL: "fibroblast activation protein: purification, epitope mapping and induction by growth factors", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 58, August 1994 (1994-08-01), pages 385 - 392, XP002114043, ISSN: 0020-7136 *
RIPPMANN JOERG F ET AL: "Procaryotic expression of single-chain variable-fragment (scFv) antibodies: Secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coli.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 64, no. 12, December 1998 (1998-12-01), pages 4862 - 4869, XP002182777, ISSN: 0099-2240 *
SCHMIDT ALEXEJ ET AL: "Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 6, March 2001 (2001-03-01), pages 1730 - 1738, XP001019035, ISSN: 0014-2956 *
WATZKA H ET AL: "Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 4, 1998, pages 279 - 291, XP004115267, ISSN: 1380-2933 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
US12240911B2 (en) 2015-10-02 2025-03-04 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40

Also Published As

Publication number Publication date
CA2401252A1 (en) 2001-09-20
AU2001256325A1 (en) 2001-09-24
EP1268550A2 (en) 2003-01-02
WO2001068708A9 (en) 2003-05-22
WO2001068708A2 (en) 2001-09-20
JP2003530092A (en) 2003-10-14

Similar Documents

Publication Publication Date Title
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
IL203894A (en) Use of a polypeptide in the manufacture of a medicament for inducing angiogenesis or liver regeneration
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
SI1583774T1 (en) Methods for preventing and treating alzheimer's disease (ad)
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HUP0600688A2 (en) Methods of administering anti-tnf alpha antibodies
WO2005012493A3 (en) Anti-cd19 antibodies
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
MX2007013626A (en) Antibodies directed against amyloid-beta peptide and methods using same.
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2000078344A8 (en) Prion protein peptides and uses thereof
WO2001064877A3 (en) Human schizophrenia gene
DE60232862D1 (en) RECOMBINANT POX VIRUS FOR CHIMERIC PROTEINS OF THE HUMAN IMMUNE WEAK VIRUS
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2001064876A3 (en) Human schizophrenia gene
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003055440A3 (en) Compositions and methods for the treatement of immune related diseases
WO2001002429A3 (en) Angiopoietin-6 and uses thereof
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BG BR CA CN CO CZ EE HR HU ID IL IN JP KR LT LV MX NO NZ PL RO SG SI SK UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2401252

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001929604

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 567798

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/2002/009066

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001929604

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/25-25/25, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2001929604

Country of ref document: EP